KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Short term Debt (2016 - 2026)

Gsk has reported Short term Debt over the past 13 years, most recently at -$7.1 billion for Q1 2026.

  • For Q1 2026, Short term Debt rose 3.49% year-over-year to -$7.1 billion; the TTM value through Mar 2026 reached -$7.1 billion, up 3.49%, while the annual FY2025 figure was -$7.2 billion, 337.58% down from the prior year.
  • Short term Debt for Q1 2026 was -$7.1 billion at Gsk, up from -$7.2 billion in the prior quarter.
  • Over five years, Short term Debt peaked at $3.5 billion in Q4 2023 and troughed at -$7.8 billion in Q3 2024.
  • A 5-year average of -$5.5 billion and a median of -$7.1 billion in 2026 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: skyrocketed 129.86% in 2023 and later tumbled 337.58% in 2025.
  • Year by year, Short term Debt stood at $1.5 billion in 2022, then surged by 129.86% to $3.5 billion in 2023, then fell by 13.24% to $3.0 billion in 2024, then tumbled by 337.58% to -$7.2 billion in 2025, then rose by 0.66% to -$7.1 billion in 2026.
  • Business Quant data shows Short term Debt for GSK at -$7.1 billion in Q1 2026, -$7.2 billion in Q4 2025, and -$7.5 billion in Q3 2025.